Roivan­t's ul­cer­a­tive col­i­tis drug from Pfiz­er shows promis­ing da­ta in ear­ly read­out

Roivant’s ul­cer­a­tive col­i­tis drug ac­quired from Pfiz­er last month has al­ready pro­duced pos­i­tive da­ta in the first read­out of the Phase IIb tri­al.

The com­pa­ny …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER